Peripheral Inflammatory Biomarkers in Parkinson’s Disease: Clinical Correlations and Stratification

TL;DR

This study explores how peripheral inflammatory biomarkers in Parkinson’s disease are linked to clinical features and disease progression, suggesting their potential for subgrouping patients.

Contribution

The study introduces novel peripheral inflammatory indices and identifies distinct inflammatory clusters in Parkinson’s disease patients.

Findings

NLR and SII were significantly elevated in Parkinson’s disease and strongly associated with non-motor and motor symptoms.

Cluster analysis identified a high-inflammation group with worse cognitive and autonomic function and faster disease progression.

High-inflammation clusters showed elevated cerebrospinal fluid markers of neurodegeneration.

Abstract

Growing evidence underscores neuroinflammation’s role in Parkinson’s disease (PD), with accumulating evidence suggesting a potential role for peripheral inflammation. The clinical applicability and mechanistic relevance of peripheral inflammatory biomarkers in PD remain to be fully elucidated. We analyzed data from the Parkinson’s Progression Markers Initiative (PPMI), including longitudinal clinical assessments, blood counts, cerebrospinal fluid (CSF) biomarkers, and genetic data. Six peripheral inflammatory indices were derived: neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI). Spearman correlation, multiple linear regression, and generalized estimating equations were employed to examine associations. Unsupervised k-means clustering was performed to identify distinct inflammatory clusters, with differences assessed using ANCOVA analysis. NLR and SII were significantly elevated in PD, with NLR showing the strongest association. Peripheral inflammatory biomarkers showed distinct clinical correlations, with NLR demonstrating associations with both non-motor (cognitive decline, olfactory impairment, and depression, p < 0.001) and motor symptoms (p < 0.001). SII, and SIRI showed correlations with motor progression (p < 0.001), while SII additionally associated with sleepiness disorders (p < 0.001). Cluster analysis identified two distinct inflammatory clusters: a high-inflammation cluster demonstrating significantly worse cognitive function (p = 0.008), olfactory impairment (p < 0.001), and autonomic dysfunction (p < 0.001) at baseline, along with accelerated motor (p = 0.038) and cognitive decline (p < 0.001) during follow-up. This high-inflammation cluster also showed elevated CSF neurodegeneration markers including pTau, tTau, NfL, and GFAP (p < 0.05). Peripheral inflammatory biomarkers show robust associations with clinical features in PD, highlighting their potential as markers associated with disease features and progression, and suggesting a basis for inflammatory-based subgrouping.

The online version contains supplementary material available at 10.1007/s10571-026-01708-8.

Figures